Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 to Be Presented at Upcoming ACR Meeting.-- Poster Presentations and Webcast Investor Event -- CAMBRIDGE, Mass. -- CombinatoRx, Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRXX) today announced that posters regarding its product candidates, CRx-102 and CRx-139 will be presented at the American College American College is the name of:
rheu·ma·tol·o·gy n. (ACR See riser card. ) meeting November 10-15, 2006 in Washington, DC. "CRx-139: A Novel Synergistic Drug Candidate Targeted for the Treatment of Immuno-Inflammatory Disease", E.R. Price, et.al. (Abstract #3374), will be presented on Monday, November 13, 9-11:00am ET and "CRx-102: Molecular Insight into Steroid Dissociation for CRx-102, a Clinically Active Immunomodulatory Agent", E.R. Price, et.al. (Abstract #3263), will be presented on Tuesday, November 14, 9-11:00 am ET. In addition to the poster presentations, CombinatoRx will host a webcast investor event on Sunday, November 12, 2006 from 6:00-8:00pm at the Willard Hotel in Washington, DC. The event will include presentations and a moderated Q&A panel by CRx-102 clinical investigators, Dr. Tore Kvien and Dr. John Kirwan. Formal presentations will begin at 6:30pm and interested parties may access a live webcast of the presentations by visiting the CombinatoRx website at www.combinatorx.com. CRx-102 and CRx-139 are oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. Synergistic combinations are comprised of two compounds acting together to provide a novel therapeutic effect which neither compound can achieve alone. CRx-102 contains the cardiovascular drug dipyridamole dipyridamole /di·py·rid·a·mole/ (di?pi-rid´ah-mol) a platelet inhibitor and coronary vasodilator used to prevent thromboembolism associated with mechanical heart valves, to treat transient ischemic attacks, and as an adjunct in and an unconventionally low dose of the steroid prednisolone prednisolone /pred·nis·o·lone/ (pred-nis´ah-lon) a synthetic glucocorticoid derived from cortisol, used in the form of the base or the acetate, sodium phosphate, or tebutate ester in replacement therapy for adrenocortical insufficiency, . CRx-139 contains paroxetine paroxetine /par·ox·e·tine/ (pah-rok´se-ten) a selective serotonin uptake inhibitor used as the hydrochloride salt to treat depression and obsessive-compulsive, panic, and social anxiety disorders. , an SSRI SSRI selective serotonin reuptake inhibitor. SSRI n. Selective serotonin reuptake inhibitor; a class of drugs that inhibit the reuptake of serotonin in the central nervous system, used to treat depression and other , and a low dose of the steroid prednisolone. About CombinatoRx CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit www.combinatorx.com. Forward-Looking Statement forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 concerning CombinatoRx, its product candidates and their clinical potential, its plans for its product candidates, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, assumptions regarding the mechanism of action of our product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release. (c) 2006 CombinatoRx, Incorporated. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion